The percentage of teachers who are using artificial intelligence-driven tools in their classrooms nearly doubled between 2023 and 2025, according to data from the EdWeek Research Center. In 2023, a ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Add Futurism (opens in a new tab) Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. What is it with lawyers ...

Long-Term Support release, with features ranging from structured concurrency and compact object headers to ahead-of-time method profiling and JFR CPU-time profiling on Linux, is now generally ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...

Either way, let’s not be in denial about it. Credit...Illustration by Christoph Niemann Supported by By Kevin Roose and Casey Newton Kevin Roose and Casey Newton are the hosts of The Times’s “Hard ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...